NF-κB-miR-155 axis activation mediates ovulation-induced oncogenic effects in fallopian tube epithelium.


Journal

Carcinogenesis
ISSN: 1460-2180
Titre abrégé: Carcinogenesis
Pays: England
ID NLM: 8008055

Informations de publication

Date de publication:
31 12 2020
Historique:
received: 03 02 2020
revised: 15 06 2020
accepted: 24 06 2020
pubmed: 3 7 2020
medline: 20 5 2021
entrez: 3 7 2020
Statut: ppublish

Résumé

The fallopian tube secretory epithelial cells (FTSECs) are the cell-of-origin of most high-grade serous ovarian carcinomas (HGSOC). FTSECs are repeatedly exposed to inflammation induced by follicular fluid (FF) that is released with every ovulation cycle throughout a woman's reproductive years. Uninterrupted ovulation cycles are an established risk factor for HGSOC. Stimuli present in the FF induce an inflammatory environment which may cause DNA damage eventually leading to serous tumorigenesis. With the aim of elucidating possible mechanistic pathways, we established an 'ex vivo persistent ovulation model' mimicking the repeated exposure of human benign fallopian tube epithelium (FTE) to FF. We performed mass spectrometry analysis of the secretome of the ex vivo cultures as well as confirmatory targeted expressional and functional analyses. We demonstrated activation of the NF-κB pathway and upregulation of miR-155 following short-term exposure of FTE to human FF. Increased expression of miR-155 was also detected in primary HGSOC tumors compared with benign primary human FTE and corresponded with changes in the expression of miR-155 target genes. The phenotype of miR-155 overexpression in FTSEC cell line is of increased migratory and altered adhesion capacities. Overall, activation of the NF-κB-miR-155 axis in FTE may represent a possible link between ovulation-induced inflammation, DNA damage, and transcriptional changes that may eventually lead to serious carcinogenesis.

Identifiants

pubmed: 32614381
pii: 5866461
doi: 10.1093/carcin/bgaa068
doi:

Substances chimiques

Biomarkers, Tumor 0
MIRN155 microRNA, human 0
MicroRNAs 0
NF-kappa B 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1703-1712

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Auteurs

Hadar Brand (H)

Sheba Cancer Research Center, Chaim Sheba Medical Center, Ramat Gan, Israel.
Sackler Faculty of Medicine, Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel.

Georgina D Barnabas (GD)

Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel.

Stav Sapoznik (S)

Sheba Cancer Research Center, Chaim Sheba Medical Center, Ramat Gan, Israel.

Keren Bahar-Shany (K)

Sheba Cancer Research Center, Chaim Sheba Medical Center, Ramat Gan, Israel.

Yair Pozniak (Y)

Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel.

Yuval Yung (Y)

IVF Unit and Reproduction Lab, Department of Obstetrics and Gynecology, Chaim Sheba Medical Center, Ramat Gan, Israel.

Ariel Hourvitz (A)

Sackler Faculty of Medicine, Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel.
IVF Unit and Reproduction Lab, Department of Obstetrics and Gynecology, Chaim Sheba Medical Center, Ramat Gan, Israel.

Tamar Geiger (T)

Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel.

Jasmine Jacob-Hirsch (J)

Sheba Cancer Research Center, Chaim Sheba Medical Center, Ramat Gan, Israel.

Keren Levanon (K)

Sheba Cancer Research Center, Chaim Sheba Medical Center, Ramat Gan, Israel.
Sackler Faculty of Medicine, Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH